Literature DB >> 6086302

Interaction of anticonvulsant drugs with adenosine receptors in the central nervous system.

R L Weir, W Padgett, J W Daly, S M Anderson.   

Abstract

The anticonvulsant carbamazepine inhibits binding of 1 nM [3H]N6-cyclohexyladenosine to rat cerebral and cerebellar A1 adenosine receptors with an IC50 value of about 50 microM. This concentration is well within that expected for therapeutic regimens. Other anticonvulsants such as phenobarbital, phenytoin, primidone, valproate sodium, and ethosuximide had little or no effect on binding, while theophylline and caffeine caused marked inhibition. Carbamazepine had no marked effect on cyclic AMP levels in guinea pig cerebral cortical or hippocampal slices, but was a weak inhibitor (IC50 about 200 microM) of 2-chloroadenosine-elicited accumulations of cyclic AMP via an A2 adenosine receptor in cortical slices. Carbamazepine is thus a somewhat selective ligand for A1 adenosine receptors in brain. The nature of its activity at those receptors is unclear, but its lack of central stimulant effects contrasts to the stimulant properties of A1 adenosine receptor antagonist such as caffeine and theophylline.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086302     DOI: 10.1111/j.1528-1157.1984.tb03449.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

1.  Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors.

Authors:  Y Fujiwara; M Sato; S Otsuki
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Differential effects of agents enhancing purinergic transmission upon the antielectroshock efficacy of carbamazepine, diphenylhydantoin, diazepam, phenobarbital, and valproate in mice.

Authors:  S J Czuczwar; B Szczepanik; A Wamil; W Janusz; Z Kleinrok
Journal:  J Neural Transm Gen Sect       Date:  1990

3.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14

4.  Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948.

Authors:  M Elphick; Z Taghavi; T Powell; P P Godfrey
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Caffeine Protects Against Anticonvulsant-Induced Neurotoxicity in the Developing Rat Brain.

Authors:  Stefanie Endesfelder; Ulrike Weichelt; Cornelia Schiller; Marco Sifringer; Ivo Bendix; Christoph Bührer
Journal:  Neurotox Res       Date:  2017-06-22       Impact factor: 3.911

6.  Influence of CGS 15943 A (a nonxanthine adenosine antagonist) on the protection offered by a variety of antiepileptic drugs against maximal electroshock-induced seizures in mice.

Authors:  S J Czuczwar; W Janusz; B Szczepanik; Z Kleinrok
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline.

Authors:  P Wlaź; Z Roliński; Z Kleinrok; S J Czuczwar
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors.

Authors:  J W Daly; O Hong; W L Padgett; M T Shamim; K A Jacobson; D Ukena
Journal:  Biochem Pharmacol       Date:  1988-02-15       Impact factor: 5.858

9.  Antiepileptic drugs prevent changes induced by pilocarpine model of epilepsy in brain ecto-nucleotidases.

Authors:  Giana de Paula Cognato; Alessandra Nejar Bruno; Rosane Souza da Silva; Maurício Reis Bogo; João José Freitas Sarkis; Carla Denise Bonan
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

10.  Caffeine Protects Against Anticonvulsant-Induced Impaired Neurogenesis in the Developing Rat Brain.

Authors:  Stefanie Endesfelder; Ulrike Weichelt; Cornelia Schiller; Katja Winter; Clarissa von Haefen; Christoph Bührer
Journal:  Neurotox Res       Date:  2018-02-07       Impact factor: 3.911

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.